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Abstract
Rationale Studies reporting ecstasy-induced serotonin-
toxicity and (neuro)psychological dysfunctions have been
conducted in young adults. Little is known about ecstasy
effects later in life, when serotonin levels and cognition
decrease as a consequence of normal ageing.
Objective This study aimed to assess whether harmful
effects of ecstasy only add to or also interact with age-
related neuropsychological decline.
Methods Attention, verbal and visual memory, visuospatial
ability, self-reported depression, sensation-seeking and
impulsivity were assessed in middle-aged moderate to
heavy ecstasy/polydrug users (n=17) and compared with
none or very mild ecstasy using polydrug users (matched
for age, gender, intelligence and other drugs; n=16) and a
group of drug-naive controls (n=20).
Results Moderate to heavy ecstasy/polydrug users per-
formed significantly worse on a verbal memory task
than none or very mild ecstasy using polydrug users
and drug naives. Moderate and heavy ecstasy/polydrug
users also differed significantly from drug-naives on
measures of depression, sensation-seeking and impulsiv-
ity but not from none or very mild ecstasy-using
polydrug users.
Conclusion This study in middle-aged ecstasy/polydrug
users replicated findings of studies in younger ecstasy
users, showing a harmful effect of ecstasy on verbal
memory. There was no clear support for an interaction
between harmful effects of ecstasy use and age-related
memory decline or mid-life depression.
Keywords MDMA . Ecstasy . Neuropsychology .Memory .
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Introduction
Between the mid 1980s and today, numerous studies have
been conducted looking at the effects of the party drug
ecstasy or +/−3,4-methylenedioxymethamphetamine
(MDMA) on the brain and brain functions in both animals
and humans. The existing literature presents converging
evidence for ecstasy-induced damage to the brain serotonin
system (see for reviews Reneman et al. 2006). Since
serotonin is vital to mnemonic processes, cognition, mood,
impulsivity and sensation seeking (Cools et al. 2008;
Meneses 1999; Netter et al. 1996), many studies on the
effects of ecstasy have focussed on these mental functions
and behavioural characteristics. Deficits in neuropsycho-
logical functions have been reported repeatedly, with the
most consistent finding being a decline in verbal memory in
frequent ecstasy users (Gouzoulis-Mayfrank and Daumann
2006a; Kalechstein et al. 2007; Laws and Kokkalis 2007).
Findings about the effect of ecstasy use on mood,
impulsivity or sensation seeking are less conclusive. It has
been argued that elevated levels of psychopathology are
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associated with polydrug use in general rather than
specifically with the use of ecstasy (for reviews:
Gouzoulis-Mayfrank and Daumann 2006a; Gouzoulis-
Mayfrank and Daumann 2006b; Guillot 2007).
All previous studies on the sustained (neuro)psycholog-
ical effects of ecstasy have been performed in adolescents
and young adults. Little is known about the effect of
ecstasy on memory and mood later in life. With increasing
age, serotonin levels and the number of serotonin receptors
gradually reduce (Goldberg et al. 2004; McEntee and
Crook 1991; Meltzer et al. 1998; Meneses 1999). In
addition, the modulation by serotonin of other neuro-
transmitters like acetylcholine seems to decrease with age
(Richter-Levin and Segal 1996). These and other biochem-
ical changes are associated with age-related memory
decline and depression (Meltzer et al. 1998). Alzheimer’s
disease, with memory impairment as a main symptom, is
also associated with reductions in 5-HT (Lai et al. 2005)
and with a cholinergic–serotonergic imbalance (Garcia-
Alloza et al. 2005; Meltzer et al. 1998). While depressive
symptoms seem to increase with age, impulsivity and
sensation seeking are thought to dwindle with age (Zucker-
man 1994). Taken together, it is conceivable that frequent
ecstasy use leads to memory impairments and depressive
symptoms that are more severe than those observed in the
normal ageing population.
However, no research about the effects of frequent
ecstasy use on the ageing brain has been done yet, for the
simple reason that older ecstasy users are rare. Ecstasy was
introduced as a recreational drug only in the mid 1980s and
was then used mainly by youngsters. In the current study
we targeted middle-aged participants, who started to use
ecstasy in the late 1980s/early 1990s. A complication,
however, in investigating the effects of ecstasy is that most
ecstasy users also use other drugs (Gouzoulis-Mayfrank
and Daumann 2006b). Therefore, observed deficits could
also be due to the use of psychotropic substances other than
ecstasy or to a combination of other substances and ecstasy,
rather than to the use of ecstasy per se. For example,
various harmful effects of cocaine, amphetamine, cannabis
and alcohol on neuropsychological functions have been
reported in the scientific literature (e.g. Lundqvist 2005). In
order to control for the use of other substances, we
compared older, ‘first generation’ ecstasy/polydrug users
with a group of older polydrug users that had very little or
no experience with ecstasy and a group of older drug-naive
controls. Since our previous study on the specific effects of
ecstasy in a polydrug sample (Schilt et al. 2008) only
revealed decreased verbal memory, whereas other cognitive
domains remained spared, we now expected to find
performance deficits only on verbal memory tasks in
ecstasy/polydrug users compared to ecstasy-naive polydrug
users. In addition, we theorised that the effect of ecstasy on
the serotonin system may interact with the normal age-
related decrease in serotonin, and that this should become
visible in larger effect sizes than those that have been found
in younger ecstasy users.
Materials and methods
This study is a supplement to the larger Netherlands XTC
Toxicity (NeXT) study, investigating long-term ecstasy
neurotoxicity (de Win et al. 2005).
Participants and design
In a cross-sectional design, neuropsychological functions
were compared between three groups. The first group
consisted of 20 moderate to heavy ecstasy/polydrug users
(minimum 240 tablets of ecstasy lifetime). Most of these
ecstasy/polydrug users started to use ecstasy between 1987
and 1995. Two subjects started in 2000. Mean age of first
ecstasy use was on average 32 (±6) years. The second
group consisted of 18 polydrug users (minimum 50 g
cocaine and/or amphetamine and/or more than 1,000 joints
cannabis lifetime; no or very little ecstasy). Because it was
very difficult to find polydrug users who had no experience
with ecstasy, the use of a maximum of 15 tablets of ecstasy
lifetime was permitted. The third group involved 20 drug-
naive controls; social alcohol drinking (men, <21 drinks
per week; women, <14 drinks per week) and tobacco use
allowed. Inclusion criteria for all subjects were: age
between 39 and 55 years, and Dutch as native language.
Exclusion criteria for all subjects were: a major systemic,
neurological or neuropsychiatric disorder known to affect
cognition and/or mood (e.g. hyperthyroidism, Parkinson’s
disease, stroke, schizophrenia, major depression), and the
use of psychotropic medications such as 5-HT reuptake
inhibitors. Required abstinence from substances prior to
examinations was at least 10 days for (illegal) drugs and
at least 4 days for alcohol. On the day of testing,
urinalysis was performed in the drug using groups:
enzyme-multiplied immunoassay for amphetamines, ec-
stasy, opiates, cocaine, benzodiazepine, cannabis and
alcohol.
A detailed drug use history questionnaire was obtained
from all subjects. Lifetime use of ecstasy (tablets), alcohol
(units), cannabis (number of joints), amphetamines
(grams), cocaine (grams) and tobacco (cigarettes) were
measured. The Dutch Adult Reading Test (DART) was
administered to estimate verbal intelligence for description
of the sample and comparison of the groups. The DART
was chosen because it is relatively insensitive to cognitive
impairment caused by neurological disorders (Schmand et
al. 1991).
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The study was approved by the local ethics committee.
After a complete description of the study, all subjects gave
written informed consent. Subjects were paid €40 to
compensate for travel expenses.
Neuropsychological assessments
The neuropsychological test battery in the current project
includes tests that have shown to be sensitive to ecstasy-
related neurotoxicity and tests related to functions or brain
areas that are thought to be affected by ecstasy use (e.g.
prefrontal cortex, occipital cortex and hippocampus).
Attention/working memory
& Paced Auditory Serial Addition Test (PASAT; Gronwall
1977): subjects have to add numbers to a preceding
number presented by a recorded male voice. Numbers
are presented at a speed of 1.6 s per digit. The outcome
parameter is the total number of correct calculations per
trial (max. 60).
& Digit span (Wechsler 1981): subjects have to repeat a
series of digits read aloud by the examiner; first in
forward order, than in backward order. The outcome
parameter is the number of correctly reproduced series
of digits (max. 28).
Verbal memory
& A Dutch version of the Rey Auditory Verbal Learning
Test (RAVLT; Rey 1964; Van der Elst et al. 2005):
subjects have to memorise a series of 15 nouns in five
learning trials. Immediate recall is tested after each trial.
The outcome parameter is the sum of correctly
reproduced words over five trials (max. 75). Delayed
recall is measured after 20 min. Outcome parameter is
total number of correctly reproduced words (max. 15).
Visual memory
& The Memory for Designs test (Graham and Kendall
1960): the original test with 14 geometrical figures was
split into two separate tests to obtain two parallel
versions. The mode of administration was adapted to
mimic the RAVLT. After presentation of seven figures
during 5 s each, subjects have to draw the figures from
memory. This is repeated five times. Outcome param-
eter is the number of correctly reproduced elements
(max. three points per figure) in five learning trials
(max. 105). Delayed reproduction is measured after
15 min; outcome parameter is the number of correctly
reproduced elements (max. 21).
Visuospatial functioning
& A computerised and adapted version of the Judgment of
Line Orientation (JoLO) (Benton et al. 1978): the JoLO
requires subjects to identify which two of 11 lines
presented in a semicircular array have the same
orientation in a two-dimensional space as two target
lines. The original JoLO was made more difficult to
reduce its ceiling effect and to increase its sensitivity to
brain dysfunction. The target lines in our assessments
were only shown for 1 s, directly followed by the 11
lines. The outcome parameter is the number of correctly
judged pairs of lines (max. 30).
& The Mental Rotation Task (MRT; Shepard and Metzler
1971): participants are presented with 20 pairs of block
designs drawn from different points of view. They have
to judge whether pairs of designs are identical or
different. Outcome parameter is the total number of
correct answers in 6 min (max. 40).
Self-report questionnaires
Depressive symptoms
& The Beck Depression Inventory (BDI) was used to
assess current depressive symptoms (Beck et al. 1961).
The BDI consists of 21 items that measures character-
istic attitudes of depression in the week prior to
assessment; higher scores indicate more depressive
symptoms. The BDI showed high reliability and
validity (Beck and Steer 1984; Bouman and Kok 1987).
Impulsivity
& Impulsivity was assessed with The Dutch version of the
Barratt Impulsiveness Scale (BIS-11; Patton et al.
1995). The Dutch BIS-11 contains 31 self-report items
that have to be scored from 1 to 4. The total BIS-score
was used for the purpose of this study. The BIS-11 has
adequate reliability.
Sensation seeking
& Sensation seeking was measured with the Spannings
Behoefte Lijst (SBL; Feij et al. 1982; Feij and van
Zuilen 1984), a Dutch adaptation of the American
Sensation-Seeking Scale (Zuckerman and Link 1968).
The SBL contains 51 sensation-seeking items and 16 filler
items, on a five-point Likert scale. The total general
sensation-seeking score was calculated as the sum of the
four subscale scores each divided by its number of items.
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The SBL has proven to be a reliable measure for various
aspects of sensation seeking in research populations (Feij
et al. 1982; Feij and van Zuilen 1984).
Statistical analyses
Characteristics of the sample
Differences in age and DART-IQ between the groups were
analysed with one-way analyses of variance (ANOVA),
with Gabriel’s post hoc procedures where appropriate.
Group differences in gender were investigated using a
Chi-Square test. Differences in not normally distributed
drug use variables between the groups were investigated
with non-parametric Kruskal–Wallis tests and Mann–Whit-
ney post hoc analyses.
Neuropsychological assessments
Differences between the three groups in neuropsychological
test scores were analysed using univariate ANCOVA, with
Group (ecstasy/polydrug; polydrug; drug-naive) as between
group factor. Because gender, age and DART-IQ were
correlated with the cognitive outcome parameters, these
variables were added as covariates.
In order to test whether the amount of ecstasy use was
related to neuropsychological performance, we calculated
Spearman correlations between total amount of ecstasy
tablets and cognition scores in the group of ecstasy/
polydrug users.
Self-report questionnaires
Differences between the three groups in self-reported
depression and impulsivity were analysed with non-
parametric Kruskal–Wallis tests and Mann–Whitney post
hoc analyses, because these variables were not normally
distributed. Sensation seeking was analysed using univar-
iate ANCOVA, with Group (ecstasy/polydrug/drug-naive)
as between group factor.
All analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). Given the explicit
hypotheses about the effects of heavy ecstasy use on verbal
memory and depressive symptoms, scores on RAVLT and
BDI were tested one sided (α1=0.05). Because we did not
have a specific hypothesis about the effects of ecstasy on
other cognitive functions, self-reported impulsivity and
sensation-seeking (see introduction), these significance tests
were two-sided (α2=0.05). Bonferroni corrections for mul-
tiple comparisons were applied for the number of group
comparisons: ecstasy/polydrug versus polydrug and ecstasy/
polydrug versus drug naive with alpha set at 0.05/2=0.025.
Results
Characteristics of the sample
Urine drug screening revealed one subject positive on
benzodiazepines and four subjects positive on cannabis.
These five subjects were excluded from the analyses,
leaving 17 ecstasy/polydrug users, 16 polydrug users and
20 drug-naive controls for statistical analyses.
The three groups did not differ significantly in DART-IQ
(F2,50=0.53; p=0.59), age (F2,50=0.39; p=0.68) and gender
distribution (722=0.76; p=0.68; descriptives shown in
Table 1). Drug use patterns and group comparisons in drug
use are presented in Table 2. As a consequence of the
inclusion criteria, ecstasy use was relatively infrequent (10 out
of 16 subjects), and significantly lower in the polydrug group
(mean nine tablets lifetime) than in the ecstasy/polydrug group
(mean 888 tablets lifetime). No significant differences existed
between the ecstasy/polydrug group and the polydrug group
in the lifetime exposure to amphetamines, cocaine, cannabis,
alcohol and tobacco. The drug-naive group by definition did
not use illegal drugs and used significantly less alcohol and
tobacco than the ecstasy/polydrug group.
Neuropsychological testing
Descriptive data and group comparisons of neuropsycho-
logical tests are depicted in Table 3. Univariate ANCOVA
with neuropsychological test scores as dependent variables,
and gender, age and DART-IQ as covariates demonstrated a
significant group effect on RAVLT immediate recall and
RAVLT delayed recall. Post hoc analyses showed that the
RAVLT immediate and delayed recall scores of the ecstasy/
polydrug group were significantly lower than those of the
polydrug group and the drug-naive group. Adding scores on
the BDI, BIS and SBL as covariates did not change the results.
Self-report questionnaires
Groups differed significantly on the BDI, BIS and the SBL.
Post hoc analyses showed that all self-report questionnaire
scores were significantly higher in the ecstasy/polydrug group
compared to the drug-naives, but not compared to the
polydrug group, indicating the absence of a specific effect of
ecstasy use on depression, impulsivity and sensation-seeking.
Relationship between outcome parameters, amount
of ecstasy use and abstinence duration
Within the group of ecstasy/polydrug users, no significant
dose–response relationship was found between the cumu-
lative number of ecstasy tablets and RAVLT immediate
recall (Spearman’s rho=0.17; p=0.25) or RAVLT delayed
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recall (Spearman’s rho=0.28; p=0.14). Also no significant
associations were found between verbal memory perfor-
mance and abstention period (RAVLT immediate recall:
Spearman’s rho=0.14; p=0.30; RAVLT delayed recall:
Spearman’s rho=0.24; p=0.17).
To further explore whether ex-ecstasy users improve after
quitting the use of ecstasy, we divided the group of ecstasy/
polydrug users in current ecstasy users (last use <6 months;
n=11) and ex-ecstasy users (last use >18 months; n=6). Ex-
ecstasy users recalled 45.5±11.3 words on the RAVLT
immediate recall and 9.8±3.2 words on the RAVLT delayed
recall, whereas current ecstasy users recalled 43.3±6.4 and
7.7±2.4 words on immediate and delayed recall, respective-
ly. Univariate ANCOVA with test score as dependent
variable, group (current use/ex-use) as independent variable,
and age, gender, DART-IQ and number of ecstasy tablets
lifetime (log transformed) as covariates, showed that the
differences in test scores were not significant (F1,11=0.08;
p=0.78 and F1,11=1.79; p=0.21, respectively).
Discussion
Most human studies on the neuropsychological effects of
ecstasy use were conducted in adolescents and young
adults. The current study investigated the effects of ecstasy
use on neuropsychological functions in a middle-aged
sample (mean age 45.5±5.3). The results showed that
middle-aged moderate to heavy ecstasy polydrug users
performed significantly worse on a verbal memory task
compared to polydrug users who had little or no experience
with ecstasy (matched for age, verbal intelligence and
substance use other than ecstasy) and drug-naive controls.
After correction for differences in depression, impulsivity
and sensation seeking these differences remained unchanged.
Middle-aged ecstasy polydrug users showed more depressive
symptoms, and higher impulsivity and sensation-seeking
than drug-naive controls, but they did not differ from
polydrug users, who had almost no experience with ecstasy.
Effects of ecstasy on verbal memory
Our findings of a decreased verbal memory performance in
older ecstasy/polydrug users are in line with many other
studies reporting decreased memory functioning in young
ecstasy users (for review and meta-analyses: Gouzoulis-
Mayfrank and Daumann 2006a; Kalechstein et al. 2007;
Laws and Kokkalis 2007; Verbaten 2003). If the harmful
effects of ecstasy increase with ageing, one would expect to
find greater deficits in older ecstasy users compared to
Table 2 Comparison of drug use characteristics of the three groups [mean ± SD]
P (Mann–Whitney tests)
Ecstasy users (n=17) Polydrug users (n=16) Drug-naive users (n=20) XTC vs. polydrug XTC vs. drug-naive
Ecstasy n=17 n=10
Tablets lifetime 888±678 9±6 – 0.000 –
Weeks since last use 76±119 406±212 – 0.000 –
Amphetamine n=13 n=10
Grams lifetime 318±517 287±799 – ns –
Cocaine n=16 n=16
Grams lifetime 530±753 290±525 – ns –
Cannabis n=16 n=15
Joints lifetime 7,436±10,747 9,579±9,395 – ns –
Alcohol n=17 n=16 n=20
Units lifetime 31,018±32,418 39,703±29,362 11,190±11,128 ns 0.024
Tobacco n=14 n=15 n=10
Cigarettes lifetime 96,270±62,774 144,203±177,397 61,056±60,853 ns 0.012
ns non-significant
Ecstasy (n=17) Polydrug (n=16) Drug-naive (n=20)
Males/females 10/7 7/9 10/10
Age 45.6±5.3 45.0±4.5 46.3±3.6
IQ (DART score) 103±11 107±12 103±12
Table 1 Demographics of the
three groups [mean ± SD]
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younger ecstasy users, leading to larger effect sizes in the
current study in middle-aged subjects compared to the
effect sizes in studies including younger subjects. However,
this comparison of effect sizes is hampered by the fact that
most studies did not succeed in matching ecstasy users and
controls on drug use other than ecstasy. In the current study
in middle-aged subjects, differences in verbal memory
performance between ecstasy/polydrug users and polydrug
users were substantial (Cohen’s d between 0.75 and 0.84).
Effect sizes of four studies in younger populations using the
same verbal memory test as in our study, ranged between
0.29 and 1.48 (Verbaten 2003). Important to note is that in
these studies, the amount of drug use always appeared to be
lower in the control group than in the ecstasy using group
(Verbaten 2003). A meta-analysis of 12 studies on the
effects of ecstasy on cognition, showed an effect size of d=
0.85 for verbal memory (Kalechstein et al. 2007). Again,
the amount of drug use was lower in controls compared to
ecstasy users. Moreover, across those samples, the amount
of ecstasy use, abstention periods and the use of other drugs
varied substantially. Since we have compared middle-aged
abstinent ecstasy/polydrug users with controls who used
similar amounts of drugs other than ecstasy, the effect size
of 0.84 in our study is probably more striking. To
circumvent the aforementioned disparities between studies,
we compared the effect sizes of our study between ecstasy/
polydrug users and drug-naive controls with those sum-
marised by Laws and Kokkalis (2007). Laws and Kokkalis
evaluated six studies in which verbal memory performance
in ecstasy users was compared with drug-naive controls and
calculated an effect size of d=1.06 (Laws and Kokkalis
2007). In our study with middle-aged participants, the
effect size was only slightly larger (d=1.14 with Hedges’ d
correction for small sample sizes; Hedges and Olkin 1985).
Altogether, it seems too early to conclude that the harmful
effect of ecstasy on verbal memory increases with age. The
current study and the comparison with other studies in
youngsters suggest that the effects of ecstasy use and
normal ageing on memory are additive rather than
multiplicative. It is conceivable that the subjects in the
current study (39–55 years) were not old enough to allow
the detection of an age by ecstasy (multiplicative) interac-
tion. Something similar has been asserted for chronic
alcoholism (Munro et al. 2000). Therefore, follow-up of
the current study sample may provide better information
about potential age by ecstasy interactions.
Table 3 Comparison of cognitive task performance and psychopathology questionnaires between the three groups












Digit span (max. 28 series)a 14.4±2.3 17.3±3.3 16.8±4.3 3.139 2.47 0.053 – –




44.1±8.2 50.9±9.8 52.2±5.4 7.800 2.47 <0.001c 0.024c, 0.020b,c 0.000c, 0.001b,c
RAVLT delayed
(max. 15 words)a




71.6±17.4 78.5±18.9 74.6±16.2 0.262 2.47 0.770 – –
MfD delayed
(max. 21 elements)a
18.3±2.9 19.0±3.2 18.8±2.9 0.186 2.47 0.831 – –
Visuospatial ability
JOLO (max. 30 pairs)a 20.7±3.8 20.7±4.5 22.7±2.9 2.659 2.47 0.081 – –
MRT (max. 40 hits)a 18.5±6.5 16.7±6.1 20.3±4.8 2.077 2.47 0.137 – –
Mood/impulsivity/sensation seeking
Beck Depression Inventory 6.9±5.8 7.8±7.7 2.7±2.1 4.577 2.50 0.008c 0.358c 0.002c
Barratt Impulsiveness Scale 69.5±10.0 69.4±8.1 59.4±6.7 9.213 2.50 0.000 0.961 0.001
Sensation Seeking Scale 12.9±2.1 11.9±1.9 9.7±1.5 15.070 2.50 0.000 0.168 0.000
a Corrected for age, IQ and gender
b After correction for BDI, BIS and SBL
cOne-sided significance tests, α1=0.025
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Dose–response relationship
We failed to find a relationship between verbal memory
performance and lifetime amount of ecstasy tablets. This is
at odds with some other studies, including our own study in
younger ecstasy users (Fox et al. 2001; Gouzoulis-
Mayfrank et al. 2003; Quednow et al. 2006; Schilt et al.
2008), but it is in agreement with a meta-analysis of ecstasy
studies by Verbaten (2003). Perhaps it does not matter how
much ecstasy is used above a certain threshold. Another
explanation for the absence of a dose–response relationship
might be that individuals differ in genetic vulnerability
(Schilt et al. 2009), or that the study samples (including our
own) have been too small to detect a dose–response
relationship.
In the current study, no association was found between
verbal memory performance and the duration since last
ecstasy use (abstention period). Moreover, harmful effects
of ecstasy on verbal memory did not differ between
current ecstasy users (ecstasy use within the last 6 months)
and long-term abstainers (no ecstasy use in the past
1.5 years, range 1.5–8 years). This may indicate that
verbal memory decrements related to ecstasy use are not
(quickly) reversible; a finding that is in accordance with a
study of Reneman c.s. that found sustained verbal memory
deficits after an abstention period of 1 year (Reneman et
al. 2001).
Effects of ecstasy on psychopathological symptoms
In the current study, we found elevated psychopathology
scores in middle-aged ecstasy/polydrug users compared to
drug-naive subjects, but not compared to polydrug users. It
seems that depressive symptoms, impulsivity and
sensation-seeking are related to polydrug use in general
and not specifically to the use of ecstasy. This conclusion
has also been proposed by others (Gouzoulis-Mayfrank
and Daumann 2006a). However, it remains unclear
whether psychopathology predisposes to the use of drugs,
or whether psychopathology is a consequence of using
drugs.
Strengths and limitations
The study has both strengths and limitations. The most
important strengths of the study are the good match
between the groups of heavy ecstasy/polydrug users and
the group of polydrug users, and the broad range of
neuropsychological and self-report measures that was
available for all subjects. We are also well aware of the
limitations of the current study. First of all, inherent to the
cross-sectional design, pre-morbid differences cannot be
excluded. Second, the fact that some of the polydrug
controls had some experience with ecstasy complicates the
interpretation of the findings of this study. In our previous
study in novice ecstasy users, differences in verbal memory
were detected after a mean use of 3.2 tablets lifetime (Schilt
et al. 2007). However, the fact that differences between the
moderate/heavy and the none/mild groups of ecstasy user
were found makes it very likely that ecstasy use is
associated with verbal memory impairments. Of course,
the existence of an undefined, not measured confounding
factor cannot be ruled out. Nevertheless, we think that our
groups were well matched, with the only significant
difference being the amount of ecstasy use. A third
limitation is that we had to rely on self-reported drug use
histories. In addition, there was no certainty about the
purity of ecstasy tablets that were used by the subjects in
this study. In the 1980s, when most of our subjects started
with ecstasy, there was no control on the content of ecstasy
tablets yet. By 2004, drug monitoring services in The
Netherlands showed that the percentage of ecstasy tablets
containing MDMA, MDEA and/or MDA as their main
component was 97.5%. In 1997, however, this percentage
was noticeably lower: 65.9% (Trimbos-instituut 2005).
Furthermore, although acute effects of the psychoactive
substances were minimised by the requirement of a
minimal abstention period of 10 days (which turned out to
be at least 2 weeks for 98% of the participants), influence of
recent drug use on the memory results cannot be complete-
ly excluded. Finally, we did not investigate environmental
circumstances in which the drugs were used or simulta-
neous use of different drugs, while influence of these
factors may play an important role in the neuropsycholog-
ical damage of ecstasy (Parrott 2006).
Conclusion
In conclusion, this study confirms a harmful effect of
ecstasy use on verbal memory in middle-aged ecstasy/
polydrug users. The study does not provide sufficient
support for the hypothesis that the harmful effects of
ecstasy use and the age-related memory decline and late-
life depression are multiplicative. Further research, in-
cluding studies with larger sample sizes, with subjects
older than 60 years, and with a comparison group of
younger ecstasy users, are needed to better test whether
and how ecstasy use adds to the age-related decrease in
serotonin levels. Both neuropsychological assessments
and brain imaging techniques should be used in these
studies.
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